Matches in Wikidata for { <http://www.wikidata.org/entity/Q64801319> ?p ?o ?g. }
Showing items 1 to 52 of
52
with 100 items per page.
- Q64801319 description "clinical trial" @default.
- Q64801319 description "ensayu clínicu" @default.
- Q64801319 description "klinisch onderzoek" @default.
- Q64801319 description "клінічне випробування" @default.
- Q64801319 name "Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer" @default.
- Q64801319 type Item @default.
- Q64801319 label "Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer" @default.
- Q64801319 prefLabel "Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer" @default.
- Q64801319 P1132 Q64801319-EA51D188-BB48-4A1F-BA61-C4616AB9D9E0 @default.
- Q64801319 P1476 Q64801319-339F9B21-8977-4005-A9DA-456098A6FE15 @default.
- Q64801319 P17 Q64801319-51B12DE4-AB0E-4692-B27B-6884C1BEA99E @default.
- Q64801319 P17 Q64801319-55E5C14F-C41D-43DD-B5B7-2B5D0C8EF0D9 @default.
- Q64801319 P17 Q64801319-5A25E74E-D6C4-4201-87D6-4473AABA17DD @default.
- Q64801319 P17 Q64801319-61F63A47-4014-4BC3-AB65-BC1EFDE34FAA @default.
- Q64801319 P17 Q64801319-BB029893-164B-4F97-956C-50D1EDD71708 @default.
- Q64801319 P17 Q64801319-BD53D7F4-2325-4069-94ED-997F9300A117 @default.
- Q64801319 P17 Q64801319-C5C6A6D8-2EAA-4724-8C5A-6DF400AC82DA @default.
- Q64801319 P17 Q64801319-CD1F1AAB-BEC7-4710-A377-BBEA994A5D18 @default.
- Q64801319 P17 Q64801319-CE4A2080-72A0-4CD8-80FF-0C0C313A0CDB @default.
- Q64801319 P17 Q64801319-E3F69178-07EF-4089-8A0E-CA51681ADF5F @default.
- Q64801319 P17 Q64801319-E7C75B5A-09D2-46D3-9E4A-F264DAE143C9 @default.
- Q64801319 P1813 Q64801319-8145D6FB-2B93-4480-B05B-6B42FB1CD0BF @default.
- Q64801319 P2899 Q64801319-B516BFC8-4726-4128-8616-61F7FD11A9E8 @default.
- Q64801319 P3098 Q64801319-5BF19EA8-D255-4F69-9538-694F5F9B0C80 @default.
- Q64801319 P31 Q64801319-40F5C5AB-9564-4908-9387-B7617B54427C @default.
- Q64801319 P4135 Q64801319-60C73700-7B23-486C-905D-269D31CA932C @default.
- Q64801319 P580 Q64801319-94F7E8B5-3F17-42DB-BE1E-E0084D497248 @default.
- Q64801319 P582 Q64801319-71C8BBC1-57F0-4FB1-957B-D92618B53549 @default.
- Q64801319 P6099 Q64801319-D5550617-CCA4-4F31-B741-0E4D8E9105F5 @default.
- Q64801319 P8363 Q64801319-5682976E-5A8F-458A-B20B-2288FA800E0D @default.
- Q64801319 P1132 "+975" @default.
- Q64801319 P1476 "A Phase III Randomized, Open-Label, Multi-Center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) Administered as Combination Therapy Versus BCG Alone in High-Risk, BCG Naïve Non-Muscle Invasive Bladder Cancer Patients" @default.
- Q64801319 P17 Q142 @default.
- Q64801319 P17 Q145 @default.
- Q64801319 P17 Q16 @default.
- Q64801319 P17 Q17 @default.
- Q64801319 P17 Q183 @default.
- Q64801319 P17 Q29 @default.
- Q64801319 P17 Q31 @default.
- Q64801319 P17 Q36 @default.
- Q64801319 P17 Q40 @default.
- Q64801319 P17 Q408 @default.
- Q64801319 P17 Q55 @default.
- Q64801319 P1813 "POTOMAC" @default.
- Q64801319 P2899 "+18" @default.
- Q64801319 P3098 "NCT03528694" @default.
- Q64801319 P31 Q30612 @default.
- Q64801319 P4135 "+130" @default.
- Q64801319 P580 "2018-05-14T00:00:00Z" @default.
- Q64801319 P582 "2021-11-24T00:00:00Z" @default.
- Q64801319 P6099 Q42824827 @default.
- Q64801319 P8363 Q78089383 @default.